A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200525047570N1

Enrollment

Registered

2020-07-30

Start date

2020-07-31

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Covid-19 disease

Interventions

Intervention 1: Intervention Group 1 receives Tocilizumab? Vial, a humanized antibody, and an interleukin 6 receptor. A dose of 162mg/0.9ml will be administered once a week Subconsciously for two week

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Lack of a specific clinical disease Non-use of a particular drug No pregnancy

Exclusion criteria

Exclusion criteria: A specific clinical disease Taking a particular drug Pregnancy

Design outcomes

Primary

Measure	Time frame
Blood ferritin levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood C-reactive protein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood creatine Phosphokinase levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Low-density lipoprotein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Lung tissue. Timepoint: Days 1 and 14. Method of measurement: Computed tomography CT-scan.;Blood Lymphocyte levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood Neutrophil levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Partial pressure of carbon dioxide (PCO2). Timepoint: Days 1-3-7-10-14. Method of measurement: Arterial blood gas test.	—

Measure

Time frame

Blood ferritin levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood C-reactive protein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood creatine Phosphokinase levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Low-density lipoprotein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Lung tissue. Timepoint: Days 1 and 14. Method of measurement: Computed tomography CT-scan.;Blood Lymphocyte levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood Neutrophil levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Partial pressure of carbon dioxide (PCO2). Timepoint: Days 1-3-7-10-14. Method of measurement: Arterial blood gas test.

—

Secondary

Measure	Time frame
Tumor necrosis factor alpha, TNFa. Timepoint: Days 1, 3 ,7 , 14. Method of measurement: ELISA Kit.;Interleukin 1. Timepoint: Days 1 ,3 ,7 , 14. Method of measurement: ELISA Kit.;Interleukin 6. Timepoint: Days 1, 3, 7, 14. Method of measurement: ELISA Kit.;Interleukin 18. Timepoint: Days 1, 3, 7, 14. Method of measurement: ELISA Kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Hadisi

Tabriz University of Medical Sciences

nhadisi72@yahoo.com+98 44 4432 6311

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026